Ioxilan

Summary

Ioxilan (CHEMBL1201075) is an approved small molecule (ATC V08AB12).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB12
• Chemistry: 791.1 Da · C18H24I3N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201075
Name	Ioxilan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3743
ATC	V08AB12
Molecular formula	C18H24I3N3O8
Molecular weight	791.1
InChIKey	UUMLTINZBQPNGF-UHFFFAOYSA-N

SMILES: CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCCO)I

IUPAC name: 5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

Also known as: Ioxilan, Ioxilane, Ioxitol, Loxilan, NSC-760056, Oxilan, Oxilan-300, Oxilan-350, IOXILAN, SID144206678, SID170465160

Patent coverage: 1,052 distinct patent families (3,740 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).